{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:23:50Z","timestamp":1781731430842,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.avsg.2021.08.022","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:50:30Z","timestamp":1634331030000},"page":"392.e1-392.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Dabigatran Use after Argatroban for Heparin-induced Thrombocytopenia with Thrombosis: A Case Series and Literature Review"],"prefix":"10.1016","volume":"80","author":[{"given":"Yue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2021.08.022_bib0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","article-title":"Heparin-induced thrombocytopenia: a focus on thrombosis","volume":"41","author":"Arepally","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.avsg.2021.08.022_bib0002","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11239-016-1365-0","article-title":"Novel oral anticoagulants for heparin-induced thrombocytopenia","volume":"42","author":"Skelley","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.avsg.2021.08.022_bib0003","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.avsg.2021.08.022_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/17474086.1.1.75","article-title":"Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis","volume":"1","author":"Greinacher","year":"2008","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.avsg.2021.08.022_bib0005","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.avsg.2021.08.022_bib0006","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood-2005-11-012450","article-title":"Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia","volume":"108","author":"Warkentin","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.avsg.2021.08.022_bib0007","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.avsg.2021.08.022_bib0008","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1378\/chest.127.5.1857","article-title":"Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study","volume":"127","author":"Warkentin","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.avsg.2021.08.022_bib0009","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.avsg.2021.08.022_bib0010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/01.CCM.0000119426.34340.E2","article-title":"Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy","volume":"32","author":"LaMonte","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.avsg.2021.08.022_bib0011","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MBC.0b013e3283502989","article-title":"Thromboembolic complications of heparin-induced thrombocytopenia","volume":"23","author":"Giossi","year":"2012","journal-title":"Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis"},{"key":"10.1016\/j.avsg.2021.08.022_bib0012","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/15563650.2014.917181","article-title":"Heparin-induced thrombocytopenia","volume":"52","author":"Lovecchio","year":"2014","journal-title":"Clinical toxicology (Philadelphia, Pa)"},{"key":"10.1016\/j.avsg.2021.08.022_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost"},{"issue":"2 Suppl","key":"10.1016\/j.avsg.2021.08.022_bib0014","article-title":"The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment","volume":"127","author":"Kelton","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.avsg.2021.08.022_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620712443537","article-title":"Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia","volume":"3","author":"Bakchoul","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.avsg.2021.08.022_bib0016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: diagnosis and management update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.avsg.2021.08.022_bib0017","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"2 Suppl","key":"10.1016\/j.avsg.2021.08.022_bib0018","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest."},{"key":"10.1016\/j.avsg.2021.08.022_bib0019","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/17474086.2015.1087845","article-title":"Current management of heparin-induced thrombocytopenia","volume":"8","author":"Cosmi","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.avsg.2021.08.022_bib0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-2008-1066027","article-title":"The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update","volume":"34","author":"Prechel","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.avsg.2021.08.022_bib0021","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"CLINICAL PRACTICE. Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2021.08.022_bib0022","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.12059","article-title":"Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition","volume":"159","author":"Watson","year":"2012","journal-title":"Br J Haematol"},{"issue":"3 Suppl","key":"10.1016\/j.avsg.2021.08.022_bib0023","article-title":"Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Warkentin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.avsg.2021.08.022_bib0024","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.jtcvs.2015.04.054","article-title":"Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: a case report","volume":"150","author":"Abouchakra","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.avsg.2021.08.022_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MBC.0000000000000205","article-title":"Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia","volume":"26","author":"Hantson","year":"2015","journal-title":"Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis"},{"key":"10.1016\/j.avsg.2021.08.022_bib0026","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.thromres.2014.06.005","article-title":"First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia","volume":"135","author":"Ng","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.avsg.2021.08.022_bib0027","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.mayocp.2013.06.013","article-title":"Dabigatran for heparin-induced thrombocytopenia","volume":"88","author":"Anniccherico","year":"2013","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.avsg.2021.08.022_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5152\/eurasianjmed.2015.95","article-title":"Massive pulmonary embolism in a patient with heparin induced thrombocytopenia: successful treatment with dabigatran","volume":"48","author":"Bircan","year":"2016","journal-title":"Eurasian J Med"},{"key":"10.1016\/j.avsg.2021.08.022_bib0029","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1345\/aph.1Q474","article-title":"Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies","volume":"46","author":"Fieland","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.avsg.2021.08.022_bib0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ccr3.411","article-title":"Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer","volume":"3","author":"Larsen","year":"2015","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.avsg.2021.08.022_bib0031","first-page":"112","article-title":"Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia","volume":"9","author":"Mirdamadi","year":"2013","journal-title":"ARYA atherosclerosis"},{"key":"10.1016\/j.avsg.2021.08.022_bib0032","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11239-015-1208-4","article-title":"Rivaroxaban in the treatment of heparin-induced thrombocytopenia","volume":"40","author":"Sartori","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.avsg.2021.08.022_bib0033","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.thromres.2015.01.009","article-title":"New oral anticoagulants in the treatment of heparin-induced thrombocytopenia","volume":"135","author":"Sharifi","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.avsg.2021.08.022_bib0034","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH14-07-0593","article-title":"Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban","volume":"114","author":"Tardy-Poncet","year":"2015","journal-title":"Thromb Haemost"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509621007305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509621007305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:04:49Z","timestamp":1760187889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509621007305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":34,"alternative-id":["S0890509621007305"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2021.08.022","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dabigatran Use after Argatroban for Heparin-induced Thrombocytopenia with Thrombosis: A Case Series and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2021.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}